At the moment, the pandemic shows no signs of slowing.
To date, there are nearly 33.4 million cases, with 1.002 million deaths. In the U.S., cases are up to 7.15 million. Brazil is up to 4.7 million. India is nearing 6.2 million. Russia is now up to 1.16 million. Meanwhile, the World Health Organization has warned the situation could get far worse, meaning we need treatment immediately.
However, we may be getting closer to a vaccine.
Shares of Moderna Inc. (MRNA) pushed higher after noting its early-stage study data suggests its COVID-19 vaccine can generate neutralizing antibodies in elderly adults, as reported by MarketWatch. The study was published in The New England Journal of Medicine.
“Given the increased morbidity and mortality of COVID-19 in older and elderly adults, these data give us optimism in demonstrating mRNA-1273’s protection in this population, which is being evaluated in the Phase 3 COVE study,” said al Zaks, M.D., Ph.D., Chief Medical Officer.
Shares of Regeneron Pharmaceuticals (REGN) are $25 higher after saying its “experimental two-antibody cocktail reduced viral levels and improved symptoms in non-hospitalized patients with mild-to-moderate Covid-19,” according to NBC News.
“Results for the first 275 trial patients showed the greatest effect in patients who had not mounted their own immune response prior to treatment, suggesting that REGN-COV2 could provide a therapeutic substitute for the naturally-occurring immune response.”